April 25, 2025

FDA Approves Penpulimab-kcqx for NPC

The FDA approved penpulimab-kcqx for first line and previously treated recurrent or metastatic non-keratinizing nasopharyngeal carcinoma.

Conexiant

April 25, 2025

Gut-Friendly Diet Linked to Lower Diabetes Risk

A study of over ten thousand US adults found that a gut-friendly diet was linked to lower risk of type 2 diabetes and insulin resistance.

Conexiant

April 25, 2025

FDA Approves Anti–PD-1 Antibody for Nasopharyngeal Cancer

The FDA has approved the humanized IgG1 monoclonal anti–PD-1 antibody penpulimab-kcqx with cisplatin or carboplatin and gemcitabine for the first-line treatment of adults with recurrent or metastatic ...

The ASCO Post

April 24, 2025

Vitamin D Multifaceted CRC Immunomodulator Revealed

"Vitamin D enhances immune organ functions such as the spleen and lymph nodes, and boosts T-cell activity, which is essential in defending the body against tumors."

Conexiant

April 24, 2025

Pembrolizumab Plus Chemotherapy: New Standard of Care in Locally Advanced Cervical Cancer?

Updated findings from the second planned interim analysis of the phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 study solidify the PD-1 inhibitor pembrolizumab plus concurrent chemoradiotherapy, followed b...

The ASCO Post

April 23, 2025

Sense of Belonging 'Critical' for Workplace Retention

Individuals who reported a neutral level of satisfaction with their sense of belonging were approximately 3 times more likely to express an intent to leave, while those who were dissatisfied were 7 times more likely to do so, compared to individuals who were satisfied with their sense of belonging.

Conexiant

April 22, 2025

Heavy Metals Found in Toothpaste

There are some "heavy metals that are essential in small quantities but could result in adverse effects if present in excess."

Conexiant

April 21, 2025

Lupus Clusters Show Distinct Disease Patterns

Cluster 2 patients exhibited ‘a more severe form of the disease, marked with frequent serositis and haematological manifestations, renal and neurological involvement,’ and had poorer outcomes over time.

Conexiant

April 18, 2025

FDA Approves New Spontaneous Urticaria Therapy

The FDA approved dupilumab as the first targeted therapy for chronic spontaneous urticaria in patients aged 12 years and older uncontrolled on antihistamines.

Conexiant